The Pyk2 FERM domain as a target to inhibit glioma migration

Joseph C Loftus, Zhongbo Yang, Nhan Tran, Jean Kloss, Carole Viso, Michael E. Berens, Christopher A. Lipinski

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The invasion of malignant glioma cells into the surrounding normal brain precludes effective clinical treatment. In this report, we investigated the role of the NH2-terminal FERM domain in the regulation of the promigratory function of Pyk2. We report that the substitution of residues that constitute a small cleft on the surface of the F3 module of the FERM domain do not significantly alter Pyk2 expression but result in the loss of Pyk2 phosphorylation. A monoclonal antibody, designated 12A10, specifically targeting the Pyk2 FERM domain was generated and recognizes an epitope located on the β5C-α1C surface of the F3 module of the FERM domain. Amino acid substitutions in the F3 module that resulted in the loss of Pyk2 phosphorylation also inhibited the binding of 12A10, suggesting that the 12A10 epitope overlaps a site that plays a role in Pyk2 activity. Conjugation of 12A10 to a membrane transport peptide led to intracellular accumulation and inhibition of glioma cell migration in a concentration-dependent manner. A single chain Fv fragment of 12A10 was stable when expressed in the intracellular environment, interacted directly with Pyk2, reduced Pyk2 phosphorylation, and inhibited glioma cell migration in vitro. Stable intracellular expression of the 12A10 scFv significantly extended survival in a glioma xenograft model. Together, these data substantiate a central role for the FERM domain in regulation of Pyk2 activity and identify the F3 module as a novel target to inhibit Pyk2 activity and inhibit glioma progression.

Original languageEnglish (US)
Pages (from-to)1505-1514
Number of pages10
JournalMolecular Cancer Therapeutics
Volume8
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Glioma
Phosphorylation
Epitopes
Cell Migration Inhibition
Immunoglobulin Variable Region
Single-Chain Antibodies
Amino Acid Substitution
Heterografts
Cell Movement
Monoclonal Antibodies
Peptides
Membranes
Brain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The Pyk2 FERM domain as a target to inhibit glioma migration. / Loftus, Joseph C; Yang, Zhongbo; Tran, Nhan; Kloss, Jean; Viso, Carole; Berens, Michael E.; Lipinski, Christopher A.

In: Molecular Cancer Therapeutics, Vol. 8, No. 6, 06.2009, p. 1505-1514.

Research output: Contribution to journalArticle

Loftus, Joseph C ; Yang, Zhongbo ; Tran, Nhan ; Kloss, Jean ; Viso, Carole ; Berens, Michael E. ; Lipinski, Christopher A. / The Pyk2 FERM domain as a target to inhibit glioma migration. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 6. pp. 1505-1514.
@article{967c519d2a4042a89d7a8416c3788489,
title = "The Pyk2 FERM domain as a target to inhibit glioma migration",
abstract = "The invasion of malignant glioma cells into the surrounding normal brain precludes effective clinical treatment. In this report, we investigated the role of the NH2-terminal FERM domain in the regulation of the promigratory function of Pyk2. We report that the substitution of residues that constitute a small cleft on the surface of the F3 module of the FERM domain do not significantly alter Pyk2 expression but result in the loss of Pyk2 phosphorylation. A monoclonal antibody, designated 12A10, specifically targeting the Pyk2 FERM domain was generated and recognizes an epitope located on the β5C-α1C surface of the F3 module of the FERM domain. Amino acid substitutions in the F3 module that resulted in the loss of Pyk2 phosphorylation also inhibited the binding of 12A10, suggesting that the 12A10 epitope overlaps a site that plays a role in Pyk2 activity. Conjugation of 12A10 to a membrane transport peptide led to intracellular accumulation and inhibition of glioma cell migration in a concentration-dependent manner. A single chain Fv fragment of 12A10 was stable when expressed in the intracellular environment, interacted directly with Pyk2, reduced Pyk2 phosphorylation, and inhibited glioma cell migration in vitro. Stable intracellular expression of the 12A10 scFv significantly extended survival in a glioma xenograft model. Together, these data substantiate a central role for the FERM domain in regulation of Pyk2 activity and identify the F3 module as a novel target to inhibit Pyk2 activity and inhibit glioma progression.",
author = "Loftus, {Joseph C} and Zhongbo Yang and Nhan Tran and Jean Kloss and Carole Viso and Berens, {Michael E.} and Lipinski, {Christopher A.}",
year = "2009",
month = "6",
doi = "10.1158/1535-7163.MCT-08-1055",
language = "English (US)",
volume = "8",
pages = "1505--1514",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - The Pyk2 FERM domain as a target to inhibit glioma migration

AU - Loftus, Joseph C

AU - Yang, Zhongbo

AU - Tran, Nhan

AU - Kloss, Jean

AU - Viso, Carole

AU - Berens, Michael E.

AU - Lipinski, Christopher A.

PY - 2009/6

Y1 - 2009/6

N2 - The invasion of malignant glioma cells into the surrounding normal brain precludes effective clinical treatment. In this report, we investigated the role of the NH2-terminal FERM domain in the regulation of the promigratory function of Pyk2. We report that the substitution of residues that constitute a small cleft on the surface of the F3 module of the FERM domain do not significantly alter Pyk2 expression but result in the loss of Pyk2 phosphorylation. A monoclonal antibody, designated 12A10, specifically targeting the Pyk2 FERM domain was generated and recognizes an epitope located on the β5C-α1C surface of the F3 module of the FERM domain. Amino acid substitutions in the F3 module that resulted in the loss of Pyk2 phosphorylation also inhibited the binding of 12A10, suggesting that the 12A10 epitope overlaps a site that plays a role in Pyk2 activity. Conjugation of 12A10 to a membrane transport peptide led to intracellular accumulation and inhibition of glioma cell migration in a concentration-dependent manner. A single chain Fv fragment of 12A10 was stable when expressed in the intracellular environment, interacted directly with Pyk2, reduced Pyk2 phosphorylation, and inhibited glioma cell migration in vitro. Stable intracellular expression of the 12A10 scFv significantly extended survival in a glioma xenograft model. Together, these data substantiate a central role for the FERM domain in regulation of Pyk2 activity and identify the F3 module as a novel target to inhibit Pyk2 activity and inhibit glioma progression.

AB - The invasion of malignant glioma cells into the surrounding normal brain precludes effective clinical treatment. In this report, we investigated the role of the NH2-terminal FERM domain in the regulation of the promigratory function of Pyk2. We report that the substitution of residues that constitute a small cleft on the surface of the F3 module of the FERM domain do not significantly alter Pyk2 expression but result in the loss of Pyk2 phosphorylation. A monoclonal antibody, designated 12A10, specifically targeting the Pyk2 FERM domain was generated and recognizes an epitope located on the β5C-α1C surface of the F3 module of the FERM domain. Amino acid substitutions in the F3 module that resulted in the loss of Pyk2 phosphorylation also inhibited the binding of 12A10, suggesting that the 12A10 epitope overlaps a site that plays a role in Pyk2 activity. Conjugation of 12A10 to a membrane transport peptide led to intracellular accumulation and inhibition of glioma cell migration in a concentration-dependent manner. A single chain Fv fragment of 12A10 was stable when expressed in the intracellular environment, interacted directly with Pyk2, reduced Pyk2 phosphorylation, and inhibited glioma cell migration in vitro. Stable intracellular expression of the 12A10 scFv significantly extended survival in a glioma xenograft model. Together, these data substantiate a central role for the FERM domain in regulation of Pyk2 activity and identify the F3 module as a novel target to inhibit Pyk2 activity and inhibit glioma progression.

UR - http://www.scopus.com/inward/record.url?scp=67649364196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649364196&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-1055

DO - 10.1158/1535-7163.MCT-08-1055

M3 - Article

C2 - 19509258

AN - SCOPUS:67649364196

VL - 8

SP - 1505

EP - 1514

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -